phrykt

Phathom Pharmaceuticals, Inc. (PHAT): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of PHAT were reported in the last 12 months. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Phathom Pharmaceuticals

From the latest filings

Overall: about as much buying as selling. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns PHAT

161 funds and institutions reported PHAT shares worth $786M at the end of Q2 2026, about 91% of the company. The largest holder is Frazier Life Sciences Management, L.P. with 15.6%.

Funds and institutions (13F) 91%Everyone else 9%

10 largest owners, by share of the company

Frazier Life Sciences Management, L.P.15.6%
Medicxi Ventures Management (Jersey) Ltd9.4%
BlackRock, Inc.5.7%
Invesco Ltd.5.1%
Carlyle Group Inc.4.4%
Millennium Management LLC4.2%
Vanguard Capital Management LLC3.3%
GW&K Investment Management, LLC2.7%
Franklin Resources Inc2.5%
NEA Management Company, LLC2.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Frazier Life Sciences Management, L.P.12.47M15.63%$135MNo change
Medicxi Ventures Management (Jersey) Ltd7.46M9.36%$81MNo change
BlackRock, Inc.4.53M5.67%$49.1M+11%
Invesco Ltd.4.03M5.05%$43.7M-7%
Carlyle Group Inc.3.50M4.38%$37.9MNo change
Millennium Management LLC3.38M4.23%$36.6M-16%
Vanguard Capital Management LLC2.66M3.33%$28.8M+3%
GW&K Investment Management, LLC2.17M2.72%$23.5M+52%
Franklin Resources Inc1.97M2.47%$21.4M+98%
NEA Management Company, LLC1.96M2.46%$21.3MNo change
683 Capital Management, LLC1.85M2.32%$20.1MNo change
Goldman Sachs Group Inc1.78M2.23%$19.3M+184%
State Street Corp1.59M1.99%$17.2M+14%
Catalys Pacific, LLC1.49M1.87%$16.2MNo change
Nomura Asset Management International Inc.1.46M1.83%$15.9M+21%
Geode Capital Management, LLC1.32M1.65%$14.3M-1%
Wasatch Advisors LP1.31M1.64%$14.2M-3%
Ensign Peak Advisors, Inc1.05M1.32%$11.4M-35%
Propel Bio Management, LLC1.05M1.32%$11.4M+25%
Point72 Asset Management, L.P.1.02M1.28%$11.1M–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No PHAT insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

PHAT short interest

High short interest. 11.3% of PHAT shares are sold short: about 1 share in 9. Over the last 12 reports the number of shares short went down 11%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 9.20M PHAT shares were sold short, 11.3% of the shares outstanding, down 5.9% from the report before. At the average daily volume of 1.90M shares, buying them all back would take about 4.8 trading days (days to cover).

Shares short, % of all shares

11.3%May 15Oct 3017.2%

Days to cover

4.8May 15Oct 3012.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20269.20M11.32%-6%1.90M4.8
Oct 15, 20269.78M12.09%-3%1.41M6.9
Sep 30, 202610.11M12.50%-0%1.37M7.4
Sep 15, 202610.16M12.56%-6%1.11M9.1
Aug 31, 202610.82M13.38%-8%983,43211.0
Aug 14, 202611.77M14.55%-12%1.71M6.9
Jul 31, 202613.33M16.47%+10%1.53M8.7
Jul 15, 202612.12M15.20%+1%1.35M9.0
Jun 30, 202611.99M15.04%+7%1.03M11.7
Jun 15, 202611.16M14.00%+8%1.08M10.4
May 29, 202610.35M12.98%+1%1.10M9.4
May 15, 202610.29M12.90%+6%1.19M8.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Phathom Pharmaceuticals company events

Phathom Pharmaceuticals filed 11 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Oct 29, 2026.

  1. Oct 29, 2026ResultsReleased financial results. Filing
  2. Oct 26, 2026AnnouncementPhathom Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration’s establishment of a public docket (Docket No. FDA-2026-N-13038) to solicit comment on legal and regulatory questions regarding certain issues raised by a filer of an abbreviated new drug application referencing VOQUEZNA… Filing
  3. Oct 23, 2026AnnouncementPhathom Pharmaceuticals, Inc. announced that BDR Pharmaceuticals International Pvt. Filing
  4. Sep 29, 2026AnnouncementPhathom Pharmaceuticals, Inc. announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed (PRN or on-demand) investigational dosing regimen of VOQUEZNA (vonoprazan) tablets in adults with Non-Erosive Gastroesophageal Reflux Disease, or… Filing
  5. Jul 30, 2026ResultsReleased financial results. Filing
  6. Jun 23, 2026AnnouncementPhathom Pharmaceuticals, Inc. announced it has completed enrollment in its Phase 2 pHalcon-EoE-201 clinical trial evaluating VOQUEZNA ® (vonoprazan) tablets as an investigational treatment for eosinophilic esophagitis in adults. Filing
  7. May 21, 2026VoteReported shareholder vote results. Filing
  8. Apr 30, 2026ResultsReleased financial results. Filing
  9. Feb 26, 2026ResultsReleased financial results. Filing
  10. Jan 8, 2026AnnouncementPhathom Pharmaceuticals, Inc. entered into an underwriting agreement with Guggenheim Securities, LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein, relating to the issuance and sale of (i) 6,875,000 shares of the Company’s common stock, par value $0.0001… Filing
  11. Jan 7, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Phathom Pharmaceuticals financials

Famous investors that hold PHAT

5 of the 50 well-known investors we track reported holding PHAT in their latest 13F filing. The largest position is Israel Englander's, worth $17.5M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20262.40M$17.5M0.0%-29%
Steve Cohen · Point72 Asset ManagementQ3 20261.50M$11M0.0%+47%
Ken Griffin · Citadel AdvisorsQ3 2026343,670$2.5M0.0%+86%
Jim Simons · Renaissance TechnologiesQ3 202621,909$160K0.0%-90%
Paul Tudor Jones · Tudor Investment CorpQ3 202616,530$121K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named PHAT in the last 120 days.

FiledHolderFormStake
Nov 10, 2026Invesco Ltd.13G/A0.0%
Nov 10, 2026Invesco Ltd.13G/A0.0%
Nov 2, 2026Frazier Life Sciences Public Fund, L.P.13D/A6.5%
Nov 2, 2026Frazier Life Sciences Public Fund, L.P.13D/A6.5%

Questions about Phathom Pharmaceuticals, Inc. (PHAT) stock

Who owns the most PHAT stock?

The largest reported owner of Phathom Pharmaceuticals, Inc. (PHAT) is Frazier Life Sciences Management, L.P., with 15.6% of the company. In total, 161 funds and institutions reported holding PHAT at the end of Q2 2026, together about 91% of the shares. See the largest owners.

Are PHAT insiders buying or selling?

No PHAT insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in PHAT?

As of Oct 30, 2026, 9.20M PHAT shares were sold short, 11.3% of the shares outstanding, down 5.9% from the report before. At the average daily volume of 1.90M shares, buying them all back would take about 4.8 trading days (days to cover). See the history.

Which famous investors hold PHAT?

5 of the 50 well-known investors we track reported PHAT in their latest 13F filing, including Israel Englander, Steve Cohen, Ken Griffin. The largest position is worth $17.5M. See all holders.

Executive pay

Phathom Pharmaceuticals's chief executive was paid a total of $3.6M for the year ended Dec 31, 2024, up 5% from $3.4M the year before. In the last 12 months, Phathom Pharmaceuticals's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$3.6MYear ended Dec 31, 2024. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$3.8MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.5MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.